Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH Names Leadership, Research Units for Restructured HIV/AIDS Clinical Trials Networks

Published: Wednesday, December 18, 2013
Last Updated: Tuesday, December 17, 2013
Bookmark and Share
Networks will lead HIV/AIDS clinical trials research through 2021.

Principal investigators and clinical trials units (CTUs) have been chosen to lead and conduct the research of five HIV/AIDS clinical trials networks through 2021.

The effort is directed and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Total funding for the networks’ leadership and the CTUs is expected to reach $225 million in 2014, the first year of operation.

“With much recent progress, this is a very exciting time in HIV/AIDS research. The next seven years will be a critical period as we pursue the now-achievable goal of an AIDS-free generation, one in which new infections and deaths from AIDS are very rare,” said NIAID Director Anthony S. Fauci, M.D. “These new awards position us to build upon the success of our current HIV/AIDS clinical research infrastructure by creating a broader, more flexible, and more collaborative approach to domestic and global HIV/AIDS research priorities.”

Planning for restructuring of the HIV/AIDS clinical trials networks began in 2010 and involved extensive consultations with researchers, clinicians, nurses, patient advocates and other activists, and people living with HIV or at risk for infection.

The new awards are intended to expand the scope of the network’s current activities to include the treatment and prevention of other infectious diseases, notably tuberculosis and hepatitis, which are the most significant co-infections for people who are infected with HIV or at risk for infection.

The new structure is designed to increase collaboration across the networks, create transparent mechanisms for network leaders to solicit and support ideas from the research community, and develop a means for external researchers to tap into the networks’ clinical trial infrastructure and capacity.

Leadership Groups
Each leadership group will be led by one or more principal investigators and include a core operations group, a central laboratory and a statistical and data management center. The following principal investigators and institutions will lead the five HIV/AIDS networks:

• AIDS Clinical Trials Group (ACTG): Daniel R. Kuritzkes, M.D.; Brigham and Women’s Hospital, Boston
• HIV Prevention Trials Network (HPTN): Wafaa El-Sadr, M.D., M.P.H., and Myron Cohen, M.D.; Family Health International, Durham, N.C.
• HIV Vaccine Trials Network (HVTN): Lawrence Corey, M.D., Glenda Gray, M.B.B.Ch., and Scott Hammer, M.D.; The Fred Hutchinson Cancer Research Center, Seattle
• International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network: Jay Brooks Jackson, M.D.; Johns Hopkins University School of Medicine, Baltimore
• Microbicide Trials Network (MTN): Sharon L. Hillier, Ph.D., and Ian Michael McGowan, M.D., Ph.D.; Magee-Womens Research Institute and Foundation, Pittsburgh

The leadership groups will have overall responsibility for developing, implementing and adapting clinical research agendas to address NIAID’s HIV/AIDS scientific priorities, including

• Therapeutics for HIV/AIDS and HIV-associated infections in adults (including HIV cure, as well as co-occurring noninfectious and infectious diseases, including hepatitis and tuberculosis).
• HIV/AIDS and HIV-associated infections in children and mothers
• Integrated strategies to prevent HIV infection
• Vaccines to prevent HIV infection
Microbicides to prevent HIV infection

They are expected to direct, coordinate and conduct NIAID-funded HIV/AIDS clinical research worldwide in close collaboration with one another, NIAID, other partner NIH institutes, and industry, foundations, and non-governmental research organizations.

Clinical Trials Units
In addition to the leadership groups, NIAID also named the 37 CTUs responsible for implementing the scientific agendas of the networks. Each CTU includes an administrative component with performance and resource management responsibilities and clinical research sites-the hospitals, outpatient clinics, health maintenance organizations, community health centers, private physician practices and clinics where clinical trials are conducted. Each CTU will affiliate with at least two of the five HIV/AIDS networks and have the option to work with other NIAID clinical networks, including NIAID’s newly developed Antibacterial Resistance Clinical Research Network.

A principal investigator will lead each of the CTUs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

In Uveitis, Bacteria in Gut May Instruct Immune Cells to Attack the Eye
NIH scientists propose novel mechanism to explain autoimmune uveitis.
Wednesday, August 19, 2015
Novel Mechanism to Explain Autoimmune Uveitis Proposed
A new study on mice suggests that bacteria in the gut may provide a kind of training ground for immune cells to attack the eye.
Wednesday, August 19, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Thursday, May 28, 2015
For Most Children with HIV and Low Immune Cell Count, Cells Rebound After Treatment
NIH-funded study finds T-cell level returns to normal with time.
Saturday, March 28, 2015
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
Friday, March 20, 2015
Autoimmune Disease Super-Regulators Uncovered
Scientists discovered key genetic switches, called super-enhancers, involved in regulating the human immune system.
Tuesday, March 17, 2015
NIH Announces $41.5 Million in Funding for the Human Placenta Project
Better understanding of the placenta promises to improve the health of mothers and children.
Tuesday, March 03, 2015
NIH-funded Scientists Create Potential Long-acting HIV Therapeutic
New molecule also might prevent HIV infection.
Tuesday, February 24, 2015
Link Between Powerful Gene Regulatory Elements and Autoimmune Diseases Revealed
Findings point to potential drug targets.
Thursday, February 19, 2015
NIH-Sponsored HIV Vaccine Trial Launches In South Africa
Early-stage trial aims to build on RV144 results.
Thursday, February 19, 2015
Stem Cell Transplants May Halt Progression of Multiple Sclerosis
NIH-funded study yields encouraging early results.
Tuesday, December 30, 2014
Candidate H7N9 Avian Flu Vaccine Works Better With Adjuvant
Results of large NIH-sponsored trial demonstrate improved vaccine response when an adjuvant was used.
Wednesday, October 08, 2014
NIH Awards Seven New Vaccine Adjuvant Discovery Contracts
Total funding for these contracts reach approximately $70 million over five years.
Tuesday, October 07, 2014
NIH to Admit Patient Exposed to Ebola Virus for Observation
Ebola patients can be safely cared for at any hospital that follows CDC's infection control recommendations.
Wednesday, October 01, 2014
Scientific News
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!